Introduction {#Sec1}
============

Glomerular podocytes are the target of injury in most glomerular diseases. Glomerulosclerosis is a hallmark of progressive glomerular damage, and is characterized by the collapse of the glomerular tuft and mesangial matrix accumulation. Transforming growth factor-ß (TGF-ß) is a key regulator of extracellular matrix (ECM) protein synthesis in renal cells. In progressive podocyte diseases, such as focal segmental glomerulosclerosis (FSGS) (Kim et al. [@CR59]), membranous nephropathy (Kim et al. [@CR61]; Shankland et al. [@CR105]), diabetic nephropathy (Wahab et al. [@CR113]), Alport renal disease (Sayers et al. [@CR100]), and Denys-Drash syndrome (Patek et al. [@CR94]), expression of TGF-ß mRNA and/or protein is increased in podocytes. In addition, mesangial matrix expansion occurs frequently in these diseases associated with glomerulosclerosis (Lee and Koh [@CR70]; Lee and Lim [@CR71]; Patek et al. [@CR94]). TGF-ß, which is overexpressed by podocytes, may contribute to the glomerular basement membrane (GBM) thickening and mesangial matrix expansion in progressive podocyte disease (Lee [@CR69]).

Besides ECM protein synthesis, TGF-ß has effects on proliferation, hypertrophy, and apoptosis in renal cells. Podocytes are growth-arrested terminally differentiated cells, and their loss following glomerular injury may contribute to the development of FSGS (Appel et al. [@CR5]; Kriz and Le Hir [@CR67]; Mundel and Shankland [@CR91]). Yet damaged podocytes can proliferate leading to the development of cellular FSGS and even crescents (Bariety et al. [@CR8], [@CR10]; Barisoni et al. [@CR11]; Ding et al. [@CR28]; Griffin et al. [@CR37]; Moeller et al. [@CR90]; Thorner et al. [@CR111]), although Smeets et al. ([@CR107]) argued that proliferating cells in these lesions mainly originate from parietal epithelial cells. In this regard, TGF-ß, which is overexpressed by hyperplastic podocytes, may be involved in podocyte proliferation (Lee and Song [@CR73]).

This review will discuss the recent findings on the mechanisms and consequences of TGF-ß overexpression by podocytes in chronic progressive podocyte disease.

Structure of podocytes {#Sec2}
======================

Podocytes are highly differentiated polarized epithelial cells. They have a main cell body which bulges into the urinary space. The long primary (cytoplasmic) processes extend from the cell body and divide into individual foot processes, which adhere to the outer surface of the GBM. Podocytes sustain the structural integrity of the GBM and synthesize most components of the GBM. The foot processes of neighboring podocytes regularly interdigitate, leaving between them filtration slits that are bridged by the slit diaphragm (Pavenstädt et al. [@CR95]). There is a recent report documenting that the filtration slit is a heteroporous structure instead of the previously suggested zipper-like structure (Gagliardini et al. [@CR34]).

Cell-cycle regulation in podocytes {#Sec3}
==================================

Mature podocytes are terminally differentiated cells and are unable to proliferate in a wide variety of normal or disease conditions. Cell proliferation is controlled at the cell-cycle level by cell-cycle regulatory proteins. Activation of specific cyclin-dependent kinases (CDKs) by a partner cyclin in each phase of the cell cycle leads to cell proliferation. Cyclin--CDK complexes are negatively regulated by the CDK inhibitors p21, p27, and p57. The inability of podocytes to undergo proiferation in most adult diseases is most likely the consequences of a robust expression or even upregulation of the CDK inhibitors with disease progression.

Podocyte injury, however, may induce a loss of the strict cell-cycle control leading to podocyte proliferation. In the cellular lesion of FSGS, damaged podocytes seem to inhibit p27 and p57 protein expression but activate mitotic cell cyclins to promote podocyte proliferation (Wang et al. [@CR115]). Despite prevailing thoughts that podocytes proliferate in human cellular FSGS (Bariety et al. [@CR8]; Barisoni et al. [@CR11]; Chun et al. [@CR21]; Schwartz et al. [@CR104]), Smeets et al. ([@CR107]) suggested that the lesion mainly originates from parietal epithelial cells in a murine model of cellular FSGS. In any case, podocyte proliferation is not regeneration but rather represents an ominous sign of the disease progression.

Components of the GBM {#Sec4}
=====================

In the adult glomerulus, the podocyte continues to add and assemble matrix molecule to the GBM, maintaining a gel-like hydrated meshwork consisting of collagen IV, laminin, fibronectin and proteoglycan. Collagen type IV is the main component of the GBM, which includes six genetically distinct isoforms named α1(IV) to α6(IV). α3--α5(IV) chains originate solely from podocytes in both the developing and mature glomerulus (Abrahamson et al. [@CR3]). In contrast, the α1/α2(IV) collagen network seems to originate mainly from glomerular endothelial cells (Lee et al. [@CR74]) and is localized predominantly at the endothelial aspect of human GBM (Zhang and Lee [@CR123]). Laminin is the most ample glycoprotein in the GBM. Laminin-11 (α5ß2γ1) continues to be deposited in the GBM whereas the fetal laminin chains (α1, α2 and ß1) gradually disappear from the GBM (Miner [@CR88]).

The flexibility and dynamic of mature GBM require a constant turnover. Thus, podocytes not only produce GBM components but also secrete matrix-modifying enzymes, such as matrix metalloproteinase (MMP)-9 (Kang et al. [@CR53]; Ma et al. [@CR78]; McMillan et al. [@CR85]) and MMP-2 (Hayashi et al. [@CR43]; Ma et al. [@CR78]).

Activation of latent TGF-ß {#Sec5}
==========================

TGF-ß is secreted as latent complexes associated with a latency-associated peptide (LAP). TGF-ß/LAP complex is referred to as the small latent complex. Most cells secrete TGF-ß as part of a large latent complex, in which latent TGF-ß binding protein (LTBP) is linked to the small latent complex. The large latent complex is susceptible to proteolysis, within which LTBP is first cleaved, and then TGF-ß is released from LAP (Koli et al. [@CR62], [@CR63]).

Under in vitro conditions, latent TGF-ß is activated by heating, acid or alkaline treatment, irradiation, reactive oxygen species (ROS), proteases including plasmin, cathepsin, calpain, MMP-2 and MMP-9, some integrins, or thrombospondin-1 (TSP-1) (for review, see Koli et al. [@CR62]). Several activation mechanisms, such as proteolysis, TSP-1, ROS and some integrins, may exist in vivo (for review, see Lee and Song [@CR72]).

Fibrogenic TGF-ß signaling cascade in podocytes {#Sec6}
===============================================

TGF-ß is known to stimulate the production of type IV collagen, fibronectin and laminin in podocytes (Nakamura et al. [@CR92]), particularly α3(IV) collagen (Iglesias-de la Cruz et al. [@CR46]). TGF-ß signals through sequential activation of two cell surface receptor serine-threonine kinases. Smad2 and Smad3 proteins are activated by TGF-ß receptor kinases. The phosphorylated Smads form complexes with Smad4, and then translocate to the nucleus, transducing signals to the target genes (Miyazono et al. [@CR89]). In podocytes, TGF-ß1 phosphorylates Smad2 (Liu et al. [@CR76]; Schiffer et al. [@CR103]). Expression levels ofTGF-ß1, TGF-ß type II receptor and phosphorylated Smad2/Smad3 are increased in the podocytes covering the lesions of FSGS (Kim et al. [@CR59]).

TGF-ß signaling intermediates controlling cell growth {#Sec7}
=====================================================

Smad pathway {#Sec8}
------------

TGF-ß causes growth arrest in late G1 of the cell cycle through Smad2 and Smad3. In the nucleus, the Smad3--Smad4 complex can activate transcription of specific genes, such as p15 and p21 (Massague et al. [@CR83]). In injured podocytes, TGF-ß/Smad signaling is activated, which may increase p15 and p21 expression (Lee and Song [@CR73]).

TGF-ß can also induce its downstream inhibitory Smad7, which in turn inhibits Smad2/3 phosphorylation via the negative feedback mechanisms (Massague and Wotton [@CR82]). TGF-ß1 induces Smad7 synthesis in cultured podocytes (Schiffer et al. [@CR102]), in which TGF-ß1 and Smad7 each induce apoptosis (Schiffer et al. [@CR101]).

Ras/mitogen-activated protein kinase (MAPK) pathway {#Sec9}
---------------------------------------------------

TGF-ß is able to signal via Ras protein, which plays an essential role in eukaryotic cell growth. Ras is required for TGF-ß-mediated activation of extracellular signal-regulated kinase (ERK) (Hartsough et al. [@CR42]). ERK activation mediates primarily mitogenic and/or anti-apoptotic signaling (Johnson and Lapadat [@CR50]) and attenuates the nuclear accumulation of the Smads (Massague and Chen [@CR81]).

In podocytes, TGF-ß activates ERK (Liu et al. [@CR76]; Schiffer et al. [@CR103]) and p38 MAPK (Schiffer et al. [@CR101], [@CR103]). Activation of p38 MAPK is required for induction of apoptosis by TGF-ß in podocytes (Schiffer et al. [@CR101]).

Phosphatidyl inositol-3-kinase (PI3K) pathway {#Sec10}
---------------------------------------------

TGF-ß also rapidly activates anti-apoptotic mediator PI3K/AKT in podocytes, the kinetic profiles of which are similar to ERK (Schiffer et al. [@CR103]). Indeed, PI3K and ERK signals appear to be synergistically activated to mediate anti-apoptotic machinery (Davies et al. [@CR26]). In addition, TGF-ß signaling through PI3K induces the expression of monocyte chemoattractant protein-1 (MCP-1) in podocytes (Lee et al. [@CR68]), and MCP-1 is involved in podocyte proliferation (Burt et al. [@CR14]).

Chronic progressive podocyte diseases with TGF-ß overexpression {#Sec11}
===============================================================

Primary FSGS {#Sec12}
------------

FSGS is a clinicopathologic entity characterized by nephrotic syndrome and progression to end-stage renal disease. Intrarenal transcription of TGF-ß1 is increased in children with FSGS compared to those with minimal lesion, suggesting that TGF-ß1 gene transcription is indicative of progressive renal damage typical of FSGS (Strehlau et al. [@CR109]). Expression of TGF-ß1 is increased in patients with primary FSGS, particularly in podocytes of sclerotic segments (Kim et al. [@CR59]). Volume density of mesangial matrix is significantly greater in the FSGS patients than in minimal lesion cases. In patients with FSGS, the percent glomerulosclerosis correlates directly with mesangial volume per glomerulus (Lee and Lim [@CR71]).

In rats with subtotal renal ablation, TGF-ß1 is upregulated by podocytes in response to enhanced transcapillary passage of plasma proteins, which precedes the development of glomerulosclerosis (Abbate et al. [@CR1]).

Cellular lesion of FSGS {#Sec13}
-----------------------

Up to 46% of patients with primary FSGS show cellular or collapsing lesion (Chun et al. [@CR21]). The cellular lesion of FSGS comprises podocyte proliferation overlying the segmental scar. Collapsing glomerulopathy is characterized by segmental or global wrinkling of the GBM with podocyte proliferation, and may be distinguished from cellular FSGS in view of the different morphologic, etiologic and prognostic implications (Barisoni et al. [@CR12]). Yet the two terms, cellular and collapsing FSGS, had often been used interchangeably or synonymously, because the glomerular pathology of both lesions is basically identical (Bariety et al. [@CR10]; Chun et al. [@CR21]; Schwartz et al. [@CR104]). Evidence from renal allograft or repeat biopsies suggests that cellular or collapsing FSGS may be the early features of FSGS, which may evolve into the classic FSGS pattern in the course of disease progression (Bariety et al. [@CR9]; Chun et al. [@CR21]; Schwartz et al. [@CR104]).

The lesions of FSGS following primary glomerular diseases may represent the nonspecific chronic scarred phase of the disease. Indeed, cellular FSGS is present in IgA nephropathy with TGF-ß overexpression by hyperplastic podocytes (Kim et al. [@CR57]). In this regard, damaged podocytes in various glomerular diseases can proliferate with expression of TGF-ß in the course of disease progression and exacerbation, leading to the development of cellular FSGS and even crescents (Lee and Song [@CR73]).

Membranous nephropathy {#Sec14}
----------------------

In membranous nephropathy, the GBM is thickened due to the accumulation of GBM material between and around the subepithelial deposits, forming subepithelial projections or spikes. Subepithelial immune deposition, particularly complement membrane attack complex (C5b-9), promotes injury to the glomerular filtration barrier and proteinuria in passive Heymann nephritis (PHN), an experimental model of human membranous nephropathy (Couser and Nangaku [@CR24]). Upregulation of TGF-ß1, α4(IV) and α1(IV) collagens, and laminin ß2 mRNAs by podocytes is shown in patients with membranous nephropathy (Kim et al. [@CR61]). In addition, immunogold densities for polyclonal type IV collagen, α4(IV) collagen, laminin, and fibronectin are increased in the spikes (Zhang and Lee [@CR123]). Expression of TGF-ß2 is also markedly increased in podocytes in experimental membranous nephropathy (Shankland et al. [@CR105]).

Lesions of FSGS are observed in 43% of the membranous nephropathty patients, in whom the degree of mesangial expansion and GBM thickening is significantly greater than the remaining cases without FSGS (Lee and Koh [@CR70]). In PHN, mesangial volume is significantly increased together with GBM thickening (Remuzzi et al. [@CR97]).

Diabetic nephropathy {#Sec15}
--------------------

Thickening of the GBM and expansion of the mesangial matrix are hallmarks of diabetic nephropathy, which occur even within a few years after the onset of type 1 diabetes (Drummond and Mauer [@CR29]). In insulin-dependent diabetes, the collagen α3(IV) through α5(IV) chains, collagen V, laminin, fibronectin, and serum proteins contribute to the thickened GBM (Miner [@CR87]).

In human diabetic nodular glomerulosclerosis, podocytes covering the sclerotic segments show increased expression of TGF-ß1 mRNA and protein (Wahab et al. [@CR113]). Increased expression of glomerular TGF-ß1 is observed mainly in podocytes of diabetic animals (Baba et al. [@CR6]; Okada et al. [@CR93]).

Alport renal disease {#Sec16}
--------------------

Alport syndrome is primary genetic disease of the basement membrane. In the kidney, this disorder is characterized by an absence of collagen α3α4α5(IV) in the GBM, progressive thickening and multilamination of the GBM, proteinuria, and renal failure. Collagen α1/α2(IV), however, is retained throughout the GBM, together with the deposition of the fetal laminin chains α1, α2 and ß1 (Abrahamson et al. [@CR2]; Kashtan et al. [@CR54]). In podocytes of α3(IV) collagen-knockout mice with Alport renal disease, mRNA expression of TGF-ß1, α1(IV) and α2(IV) collagen, fibronectin, and laminin ß1 chain is increased (Sayers et al. [@CR100]). With disease progression, mesangial matrix and cells are increased, followed by the development of glomerulosclerosis (Gregory et al. [@CR36]; Kim et al. [@CR60]).

Denys-Drash syndrome {#Sec17}
--------------------

Wilms' tumor suppressor gene, WT1, is essential for normal podocyte function. Mutations of the WT1 induce Denys-Drash syndrome (DDS) characterized by early onset nephrotic syndrome and diffuse mesangial matrix expansion. In DDS mice, the development of glomerulosclerosis is preceded by de novo TGF-ß1 expression in podocytes, while TGF-ß1 expression is absent in the mesangium (Patek et al. [@CR94]). A gene mutation in DDS podocytes may not be sufficient to cause TGF-ß overexpression (Jin et al. [@CR49]), but in the presence of a second injury, such as intraglomerular hypertension, TGF-ß seems to be overexpressed by podocytes (Patek et al. [@CR94]). Recently, Sakairi et al. ([@CR98]) reported that TGF-ß1 downregulates WT1 expression in podocytes.

Altogether, TGF-ß is overexpressed by podocytes in progressive podocyte diseases, in which thickening of the GBM and expansion of the mesangial matrix are frequently present with the eventual development of glomerulosclerosis (Table [1](#Tab1){ref-type="table"}). Table 1Possible effects of TGF-ß on glomerular pathology in progressive podocyte diseasesDiseasesPathologyReferencesGBM thickeningGlomerulosclerosisFSGSNDYesAbbate et al. ([@CR1]); Kim et al. ([@CR59])Membranous nephropathyYesYesKim et al. ([@CR61]); Shankland et al. ([@CR105])Diabetic nephropathyYesYesChen et al. ([@CR18]); Wang et al. ([@CR114]); Wahab et al. ([@CR113])Alport syndromeYesYesSayers et al. ([@CR100]); Cosgrove et al. ([@CR23])Denys-Drash syndromeNDYesPatek et al. ([@CR94])*FSGS* Focal segmental glomerulosclerosis, *ND* not deterimined

Induction of TGF-ß by glomerular hypertension or biomechanical strain in the diseased glomeruli {#Sec18}
===============================================================================================

Glomerular hemodynamic adaptive changes, including hyperfiltration and hyperperfusion, seem to promote progressive glomerulosclerosis in patients with reduced nephron mass and diabetes (Ziyadeh and Wolf [@CR124]). The less cross-linked and possibly more elastic physical properties of the GBM in some diseased glomeruli may subject the podocytes to elevated biomechanical strain even under normal glomerular blood pressure. As the disease progresses and nephron mass is lost, glomerular hypertension develops, further exacerbating the biomechanical strain and the effector functions influenced by it (Meehan et al. [@CR86]). In the remnant kidney model of glomerular capillary hypertension, TGF-ß1 (Abbate et al. [@CR1]) and Ang II type I receptor (Durvasula et al. [@CR30]) are upregulated by podocytes. In cultured podocytes, albumin load or mechanical strain increases the levels of TGF-ß1 and Ang II, as well as TGF-ß receptors (Abbate et al. [@CR1]; Dessapt et al. [@CR27]; Durvasula et al. [@CR30]).

Together, an increase in glomerular capillary pressure may stimulate Ang II and TGF-ß1 expression in podocytes through mechanical force injury in progressive podocyte diseases (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Effects of biomechanical strain on the induction of transforming growth factor-ß (*TGF-ß*) and angiotensin II (*Ang II*) in podocytes in patients with progressive podocyte disease. Ang II does not directly stimulate TGF-ß production in podocytes, yet activates NADPH oxidase to produce reactive oxygen species, leading to the activation of latent TGF-ß

Effects of Ang II on TGF-ß signaling in podocytes {#Sec19}
=================================================

Ang II is a major active product of the renin angiotensin system (RAS), and may enhance the generation of ROS through the activation of NADPH oxidases in podocytes. Unlike mesangial cells, podocytes do not overexpress TGF-ß1 when exposed to Ang II (Chen et al. [@CR20]). Rather, Ang II-induced oxidative stress may activate latent TGF-ß and, subsequently, the TGF-ß signaling system in podocytes (Lee [@CR69]) (Fig. [1](#Fig1){ref-type="fig"}).

Studies in animal models of chronic nephropathies have documented that RAS inhibitors significantly blunt the increased renal TGF-ß production. An angiotensin-converting enzyme (ACE) inhibitor prevents TGF-ß1 overexpression in podocytes and glomerulosclerosis in rats with reduced renal mass (Abbate et al. [@CR1]). It also reduces the TGF-ß1, connective tissue growth factor (CTGF) and ECM protein overexpression in kidneys of Alport mice (Gross et al. [@CR39], [@CR40]; Gross and Kashtan [@CR38]), and limits mesangial expansion in PHN (Remuzzi et al. [@CR97]). Combined anti-TGF-ß and ACE inhibition therapy abrogates the glomerulosclerosis of diabetic nephropathy in the rat (Benigni et al. [@CR13]). In addition, administration of Ang II type I (AT~1~) receptor blocker to diabetic rats lowers glomerular expression of TGF-ß1 and vascular endothelial growth factor (VEGF) (Vieitez et al. [@CR112]).

GBM thickening in relation to TGF-ß {#Sec20}
===================================

The GBM is significantly thickened in TGF-ß1 transgenic mice as compared with wild-type animals (Krag et al. [@CR65]; Wogensen et al. [@CR117]). Aberrant deposition of fetal laminin α1, α2 and ß1 chains and α1/α2(IV) collagen appears in the GBM of transgenic mice (Chai et al. [@CR15]). In cases with membranous nephropathy and Alport syndrome, there is aberrant expression of α1/α2(IV) collagen, and laminin α1, α2 and ß1 in the thickened GBM (Abrahamson et al. [@CR2]; Cosgrove et al. [@CR23]; Fischer et al. [@CR31]; Kashtan et al. [@CR54]; Zhang and Lee [@CR123]). TGF-ß1 increased α3(IV) collagen expression in cultured mouse podocytes, although it decreased the levels of α1(IV) and α5(IV) mRNA and/or protein (Iglesias-de la Cruz et al. [@CR46]). Collectively, GBM thickening by abnormal deposition of ECM in podocytopathies could be due to the enhanced TGF-ß1 levels in podocytes (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Hypothetical pathway for transforming growth factor-ß (*TGF-ß*)-induced glomerular basement membrane (*GBM*) thickening, mesangial matrix expansion, podocyte loss, podocyte proliferation, and epithelial-mesenchymal transition (*EMT*) by podocytes in progressive podocyte disease. *CTGF* connective tissue growth factor, *ERK* extracellular signal-regulated kinase, *ILK* integrin-linked kinase, *PI3K* phosphatidyl inositol-3-kinase, *VEGF* vascular endothelial growth factor

A further potential mechanism for GBM destruction and thickening involves the action of proteolytic enzymes, such as MMPs. MMP-9 expression is increased in podocytes in experimental membranous nephropathy (McMillan et al. [@CR85]) and in human and experimental diabetic nephropathy (Li et al. [@CR75]). Levels of MMPs are increased in the glomeruli of Alport mice and kidneys of patients with Alport syndrome (Zeisberg et al. [@CR122]). The aberrant collagen α1/α2(IV) network deposited in the GBM contains fewer interchain crosslinks than wild-type GBM, and is more susceptible to proteolytic degradation by endogenously expressed MMPs (Kalluri et al. [@CR52]; Zeisberg et al. [@CR122]). Blocking the activity of specific MMPs has been shown to ameliorate the progression of glomerular pathology (Zeisberg et al. [@CR122]). In cultured podocytes, TGF-ß1 stimulates the production of MMP-9 (Li et al. [@CR75]; Liu et al. [@CR76]), and many of the MMPs (MMP-3, -9, -10, and -14) are induced by mechanical strain (Meehan et al. [@CR86]). Together, increased TGF-ß1 levels in podocytes may induce MMPs, resulting in proteolytic damage and thickening of the GBM in progressive podocyte disease.

Integrins are important cellular receptors for ECM. Type IV collagen receptors, integrin α2, are able to downregulate de novo collagen synthesis as long as the GBM is intact. Loss of integrin α2 in the nonlethal phenotype of the α2-deficient mice results in localized matrix overproduction in the GBM and increased TGF-ß and CTGF expression in the kidney (Girgert et al. [@CR35]). Thus, altered cell-matrix interaction via α2 integrin may contribute to GBM thickening in association with TGF-ß.

Podocyte loss in relation to TGF-ß: the link to glomerulosclerosis {#Sec21}
==================================================================

In podocyte diseases, enhanced TGF-ß activity in podocytes may lead to podocyte apoptosis and/or detachment with podocytopenia (Dessapt et al. [@CR27]; Lee and Song [@CR73]; Schiffer et al. [@CR101]; Wolf et al. [@CR118]) (Fig. [2](#Fig2){ref-type="fig"}). C5b-9 can induce apoptosis of podocytes in membranous nephropathy (Mundel and Shankland [@CR91]), a process that may involve TGF-ß. Apoptosis is also observed in the crescentic lesion of DDS kidneys (Yang et al. [@CR120]). In TGF-ß1 transgenic mice, podocytes undergo apoptosis at an early stage of glomerulosclerosis with overexpression of Smad7 (Schiffer et al. [@CR101]). In CD2-associated protein-deficient mice, TGF-ß-induced podocyte apoptosis is an early pathomechanism developing FSGS (Schiffer et al. [@CR103]).

Another mechanism of podocyte loss in podocyte diseases may relate to the detachment of podocytes from the GBM. α3ß1 integrin, an adhesion receptor for laminins and type IV collagen isoforms, is expressed primarily on podocytes (Kreidberg and Symons [@CR66]). Downregulation of α3ß1 integrin is observed in the podocytes of patients with primary FSGS (Chen et al. [@CR16]) and diabetes (Chen et al. [@CR17]) associated with podocytopenia. TGF-ß1 suppresses the glomerular expression of α3 integrin in nephrotic rats (Kagami et al. [@CR51]). In cultured podocytes, TGF-ß1 and mechanical stretch significantly reduce the α3ß1 integrin expression linked to decreased podocyte adhesion and increased apoptosis (Dessapt et al. [@CR27]). Thus, TGF-ß1 may reduce podocyte adhesion to the GBM via downregulation of α3ß1 integrin, resulting in podocyte depletion in podocyte diseases (Fig. [2](#Fig2){ref-type="fig"}).

Because of their limited proliferative capacity, podocyte detachment from the GBM will lead to cell depletion or drop out into urinary space. The denuded GBM may adhere to the Bowman's capsule with synechiae formation, initiating the development of FSGS (Kriz and Le Hir [@CR67]). In a rat model of progressive glomerular injury, progressive reduction in the number of podocytes preceded the development of glomerulosclerosis (Macconi et al. [@CR79]).

In summary, TGF-ß may induce podocyte apoptosis and detachment from the GBM in podocyte diseases leading to the development of glomerulosclerosis.

Epithelial-mesenchymal transition (EMT) of podocytes by TGF-ß {#Sec22}
=============================================================

TGF-ß1 suppresses the slit-diaphragm-associated protein P-cadherin, zonula occludens-1, and nephrin in cultured podocytes mediated by Snail, a key transcription factor mediating EMT, leading to podocyte dedifferentiation (Li et al. [@CR75]). In patients with FSGS and membranous nephropathy, nephrin mRNA expression by podocytes is significantly decreased as compared with minimal lesion cases (Kim et al. [@CR56]). EMT may be a potential pathway leading to podocyte dysfunction, proteinuria and glomerulosclerosis. TGF-ß1 induces integrin-linked kinase (ILK) in podocytes, and inhibition of ILK activity ameliorates podocyte Snail induction and EMT (Kang et al. [@CR53]). Expression of ILK is also increased in cellular crescents of experimental glomerulonephritis (GN) (Shimizu et al. [@CR106]), suggesting that TGF-ß1-induced ILK may lead to EMT of podocytes, contributing to the formation of cellular crescents. Together, more severe and/or longer podocyte injury induced by TGF-ß may lead to EMT via upregulation of ILK in progressive podocyte disease (Kang et al. [@CR53]; Liu [@CR77]) (Fig. [2](#Fig2){ref-type="fig"}).

Mesangial matrix expansion in podocyte diseases via activation of TGF-ß signaling {#Sec23}
=================================================================================

In patients with FSGS, membranous nephropathy and DDS, mesangial matrix expansion is frequently present in association with the development of glomerulosclerosis (Lee and Koh [@CR70]; Lee and Lim [@CR71]; Patek et al. [@CR94]). Podocyte-specific injury in transgenic mice induced mesangial expansion and glomerulosclerosis (Matsusaka et al. [@CR84]).

In Smad3-knockout diabetic mice, mesangial matrix expansion is prevented (Wang et al. [@CR114]), as shown in the anti-TGF-ß-treated or TGF-ß type II receptor-deficient diabetic mice (Chen et al. [@CR18]; Kim et al. [@CR58]; Ziyadeh et al. [@CR125]). Indeed, activation of the TGF-ß/Smad signaling in podocytes from the diseased glomeruli appears to lead to overproduction of ECM in the mesangial areas resulting in the formation of glomerulosclerosis (Lee and Song [@CR72]; Kim et al. [@CR59]; Patek et al. [@CR94]) (Table [1](#Tab1){ref-type="table"}).

Paracrine effector mechanism of CTGF and VEGF for TGF-ß to act on mesangial cells in podocytopathies {#Sec24}
====================================================================================================

The podocyte TGF-ß, the active form of which has a very short half-life in plasma (Coffey et al. [@CR22]), is unlikely to traverse the GBM to promote sclerosis in the adjacent mesangium. In this regard, some TGF-ß-induced humoral factors produced by podocytes seem to have fibrogenic effects on mesangial cells (Lee and Song [@CR72]).

CTGF is a major autocrine growth factor induced by TGF-ß. TGF-ß1 induces CTGF mRNA and protein expression in podocytes (Ito et al. [@CR48]). Expression of CTGF mRNA and/or protein in the mesangium and podocytes is upregulated in human chronic glomerular disease (Ito et al. [@CR47]; Wahab et al. [@CR113]). CTGF is increased particularly in the glomeruli of patients with mesangial matrix expansion (Suzuki et al. [@CR110]). Furthermore, induction of diabetes in podocyte-specific CTGF-transgenic mice results in an increased mesangial CTGF expression with more severe mesangial expansion than diabetic wild-type mice (Yokoi et al. [@CR121]). Treatment with the CTGF antisense oligonucleotides in diabetic mice significantly reduced mesangial matrix expansion as compared with those receiving mismatch oligonucleotides (Guha et al. [@CR41]).

VEGF is a potent angiogenic molecule and is detected predominantly in podocytes (Bailey et al. [@CR7]; Wendt et al. [@CR116]). Yet glomeruli are not sites of angiogenesis, possibly because podocytes mainly express VEGF~165~b protein, which inhibits VEGF~165~-mediated angiogenesis (Cui et al. [@CR25]). TGF-ß1 stimulates VEGF expression in podocytes (Iglesias-de la Cruz et al. [@CR46]). VEGF may play an important role in TGF-ß1-induced glomerular fibrosis (Chen et al. [@CR19], [@CR20]). Indeed, anti-VEGF attenuates mesangial matrix expansion in diabetic mice (Flyvbjerg et al. [@CR32]).

Receptors for VEGF-A include VEGFR-1, VEGFR-2 and neuropilin-1. The dominant production of VEGF-A by podocytes and the localization of VEGFR-2 on glomerular endothelial cells suggest that VEGF-A moves across the GBM, opposing the ultrafiltration gradient to move water and solutes from the capillaries into the Bowman's space (Satchell et al. [@CR99]). In fact, about one-third of VEGF secreted from podocytes would reach the capillary lumen and accumulate there, supporting the view that VEGF can move against the flow of glomerular filtration (Katavetin and Katavetin [@CR55]). It is not clear whether this is also the case for CTGF, yet the experiments performed by Yokoi et al. ([@CR121]) support that possibility.

To sum up, TGF-ß-induced CTGF and VEGF secretion by podocytes may act as a paracrine regulatory mechanism, necessary for the mesangial matrix accumulation (Fig. [2](#Fig2){ref-type="fig"}).

Role of TGF-ß/Ras/ERK signaling in podocyte proliferation in proliferative podocytopathies {#Sec25}
==========================================================================================

In cellular crescents, TGF-ß overexpression (Shimizu et al. [@CR106]) and ERK activation (Masaki et al. [@CR80]) are observed. TGF-ß signaling appears to play a central role in the development of crescentic GN by inducing the activation of ERK (Song et al. [@CR108]).

ERK activation is shown in hyperplastic podocytes from the human immunodeficiency virus (HIV)-associated nephropathy and/or idiopathic collapsing FSGS patients (He et al. [@CR44]). Cyclin D1 is a key down-stream target of ERKs (Ammit and Panettieri [@CR4]). In podocytes of HIV-transgenic mice, cyclin D1 protein is increased and the increase coincides with entry into the cell cycle (Pettermann et al. [@CR96]).

Stabilization of hypoxia-inducible factor (HIF) in mice by selective deletion of the von Hippel-Lindau gene from podocytes leads to the development of crescentic GN with expression of HIF target gene Cxcr4 in podocytes (Ding et al. [@CR28]). Cxcr4 is both required and sufficient for proliferation of podocytes in vivo. Overexpression of HIF-2 is also shown in hyperplastic podocytes from the patients with HIV-associated nephropathy and HIV-1-transgenic mice (Korgaonkar et al. [@CR64]). Activation of HIF-1 occurs via PI3K and MAPK signaling pathways (Hellwig-Bürgel et al. [@CR45]). Together, Ras/ERK and PI3K activation in podocytes could stimulate cyclin D1 expression resulting in podocyte proliferation in proliferative podocytopathies.

In cultured podocytes, TGF-ß1 does not stimulate cell proliferation (Xavier et al. [@CR119]). Yet it may induce the proliferation of injured podocytes possibly via TGF-ß-induced EMT, since TGF-ß stimulates proliferation of mesenchymal-type cells (Fukuda et al. [@CR33]). In this regard, TGF-ß1-induced Ras/ERK/PI3K activation may play a role in podocyte proliferation in proliferative podocytopathies (Fig. [2](#Fig2){ref-type="fig"}).

Conclusions {#Sec26}
===========

Biomechanical strain in progressive podocyte diseases may upregulate Ang II and TGF-ß expression in podocytes. Oxidative stress induced by Ang II may activate the latent TGF-ß in podocytes. Enhanced TGF-ß activity by podocytes may induce GBM thickening by overproduction of ECM proteins and impaired GBM degradation in podocyte diseases. It may also lead to podocyte apoptosis and detachment from the GBM together with EMT, initiating the development of glomerulosclerosis. Furthermore, activated TGF-ß/Smad signaling by podocytes may induce CTGF and VEGF overexpression, which may act as a paracrine effector mechanism on mesangial cells to stimulate mesangial matrix synthesis. In proliferative podocytopathies, TGF-ß-induced ERK activation may play a role in podocyte proliferation, possibly via TGF-ß-induced EMT of podocytes. Together, this review provides new mechanistic insights into the TGF-ß overexpression by podocytes in progressive podocyte disease. Better understanding of the activation of TGF-ß signaling by podocytes and its downstream effectors may provide novel tools for the prevention of glomerulosclerosis.
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